Why Pfizer Stock Bolted Higher in July
Mega-cap pharma stocks rarely surge by double digits over just a 30-day period. But that's exactly what Pfizer's (NYSE: PFE) stock accomplished during the month of July.
Despite facing falling sales for a host of former blockbuster medicines and the impending spin-off of its legacy products unit, Pfizer's shares gained an astounding 17.7% in value last month, according to data provided by S&P Global Market Intelligence. The pharma giant thus tacked on a remarkable $33 billion to its market cap last month.
Image source: Getty Images.
Source Fool.com